April 1, 2022—Tempus has announced plans to launch Edge, a platform that will enable pathology practices to access the company’s digital pathology AI models, during the second half of this year. The models are designed to help find actionable makers to identify potential therapeutic and clinical trial options for patients.
The portfolio of models, called Tempus Histogenomics, will feature digital pathology algorithms that use a single, whole-slide H&E image to predict the potential of biomarkers, such as microsatellite instability or homologous recombination deficiency status, in patients whose samples are not ordinarily sequenced.
To coincide with the launch of Edge, Tempus is working with pathology labs to create a nationwide network, called NAPA, which will have access to the company’s growing portfolio of AI models.